Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomization was performed by a person who was not a study interviewer or therapist using a SAS procedure and was stratified by patient performance status (self-reported ECOG scores 0 or 1 vs. 2) because this factor informs cancer treatment decision-making [33].”
From Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial (2018) · cites this paper as [33]
In the citing paper
“We are stratifying randomization by performance status because it is a key factor in MBC treatment decisions [28].”
From Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer (2020) · cites this paper as [28]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial
Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., Markesbery, W. R., Foon, K. A., & Young, B. (1998) · JAMA · doi:10.1001/jama.280.17.1485 · Cited by 1,915
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Research works printed but not linked: 1
- Network NCC. 2008. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2, ASCO-Edition 2008.
Cited by
Items 201–300 of 485
Li, Y., Li, L., Du, Q., Li, Y., Yang, H., & Li, Q. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1910705 · Cited by 19
“Hormone receptor-positive (HRþ)/human epidermal growth factor receptor 2-negative (HER2 ) breast cancer is the most common breast cancer subtype, and HRþ/HER-2 patients account for approximately 60% of all ABC patients (3).”
BackgroundInfluentialWu, Y., Li, Q., Liu, Y., Li, Y., Chen, Y., Wu, X., & Liu, X. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120817 · Cited by 21
Jacobs, C. M., Amir, E., Paterson, A. H. G., Zhu, X., & Clemons, M. J. (2015) · Journal of bone oncology · doi:10.1016/j.jbo.2015.06.001 · Cited by 19
Voigt, W. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000430 · Cited by 19
Tripathy, D., Blum, J. L., Rocque, G. B., Bardia, A., Karuturi, M. S., Cappelleri, J. C., Liu, Y., Zhang, Z., Davis, K. L., & Wang, Y. (2020) · Future Oncology · doi:10.2217/fon-2020-0573 · Cited by 21
Haq, R., & Gulasingam, P. (2016) · Current Oncology · doi:10.3747/co.23.2743 · Cited by 18
Wang, Z., Wang, M., Yang, F., Nie, W., Chen, F., Xu, J., & Guan, X. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1654-5 · Cited by 18
Metastatic breast cancer: The Odyssey of personalization
Sonnenblick, A., Ponde, N. F., & Piccart, M. J. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.07.002 · Cited by 20
McFall, T. B., Patki, M., Rosati, R., & Ratnam, M. (2015) · Oncotarget · doi:10.18632/oncotarget.5082 · Cited by 19
Guo, W., Hao, B., Luo, N., Ruan, D., Guo, X., Chen, H., Wu, H., & Sun, L. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.019 · Cited by 17
A photothermal driven chemotherapy for the treatment of metastatic melanoma
Bhatt, H., Diwan, R., Borrego, E. A., Perez, C. A., Varela-Ramírez, A., Kumar, R., Aguilera, R. J., & Nurunnabi, M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.005 · Cited by 17
Hanna, W. M., Barnes, P. J., Chang, M. C., Gilks, C. B., Magliocco, A. M., Rees, H., Quenneville, L., Robertson, S. J., Sengupta, S., & Nofech‐Mozes, S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.6092 · Cited by 17
Guo, Q., Lin, X., Ye, L., Xu, R., Dai, Y., Zhang, Y., & Chen, Q. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00633-9 · Cited by 17
Al‐Romaizan, A. N., Jaber, T. S., & Ahmed, N. S. I. (2019) · Open Chemistry · doi:10.1515/chem-2019-0097 · Cited by 18
Systemic analysis of the expression levels and prognosis of breast cancer-related cadherins
Xu, M., Liu, C., Pu, L., Lai, J., Li, J., Ning, Q., Liu, X., & Deng, S. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211010417 · Cited by 17
“Despite advancements in novel therapeutic targets and targeted drugs have enhanced the efficacy of BC treatment, 20% of metastatic BC patients has a survival rate of <5 years.(2) Furthermore, owing to tumor heterogeneity, available biomarkers are limited in their prognosis of BC.”
BackgroundPareja, F. G., Murray, M. P., Jean, R. D., Konno, F., Friedlander, M. A., Lin, O., & Edelweiss, M. (2016) · Journal of the American Society of Cytopathology · doi:10.1016/j.jasc.2016.10.001 · Cited by 17
Association of γH2AX at Diagnosis with Chemotherapy Outcome in Patients with Breast Cancer
Yang, S. X., Polley, E. C., & Nguyen, D. (2017) · Theranostics · doi:10.7150/thno.19102 · Cited by 18
Toss, A., Piacentini, F., Cortesi, L., Artuso, L., Bernardis, I., Parenti, S., Tenedini, E., Ficarra, G., Maiorana, A., Iannone, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25810 · Cited by 18
Fiste, O., Liontos, M., Koutsoukos, K., Terpos, E., Dimopoulos, M. A., & Zagouri, F. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1175 · Cited by 16
Seidensticker, M., Garlipp, B., Scholz, S., Mohnike, K., Popp, F., Steffen, I. G., Seidensticker, R., Stübs, P., Pech, M., Powerski, M. J., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1499-z · Cited by 16
Bøttcher, T. M., Cold, S., & Jensen, A. B. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1532603 · Cited by 17
“The HRþ/HER2 MBC is usually managed with highly tolerable endocrine therapy (ET) consisting of aromatase inhibitors or estrogen receptor blockers.”
ResultInfluentialRosati, R., Oppat, K. M., Huang, Y., Kim, S., & Ratnam, M. (2020) · BMC Cancer · doi:10.1186/s12885-020-07002-0 · Cited by 17
Alarfi, H., Youssef, L. A., & Salamoon, M. (2020) · Journal of Oncology · doi:10.1155/2020/4174395 · Cited by 19
“Based on the currently available therapeutic options, cure of metastatic breast cancer (MBC) is a rather elusive goal, and palliative care can only help maintain quality of life while possibly prolonging survival [3].”
Individual risk profiling for breast cancer recurrence: towards tailored follow-up schemes
Kraeima, J., Siesling, S., Vliegen, I. M. H., Klaase, J. M., & IJzerman, M. J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.401 · Cited by 16
Heart myxoma develops oncogenic and metastatic phenotype
Pacheco-Velázquez, S. C., Gallardo‐Pérez, J. C., Díaz, D., de Guevara, A. A.-L., Robledo‐Cadena, D. X., Saavedra, E., Ruiz-Godoy, L. M., Jimenez-Hernández, L. R., Vargas‐Barrón, J., Aguilar-Ponce, J. L., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02897-0 · Cited by 16
Roda, E., Luca, F. D., Locatelli, C., Ratto, D., Iorio, C. D., Savino, E., Bottone, M. G., & Rossi, P. (2020) · Molecules · doi:10.3390/molecules25225400 · Cited by 18
Comprehensive Analysis of the Expression and Prognostic Value of SPINT1/2 in Breast Carcinoma
Wu, Q., Yin, G., Luo, J., Zhang, Y., Ai, T., Tian, J., Jin, Y., Lei, J., & Liu, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.665666 · Cited by 14
[18F]Fluorodeoxyglucose PET/Computed Tomography in Breast Cancer and Gynecologic Cancers
Hildebrandt, M. G., Kodahl, A. R., Teilmann-Jørgensen, D., Mogensen, O. E., & Jensen, P. T. (2014) · PET Clinics · doi:10.1016/j.cpet.2014.09.007 · Cited by 14
Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
Cortés, J. (2011) · OncoTargets and Therapy · doi:10.2147/ott.s16392 · Cited by 14
Bergamino, M. A., Fernández-Ortega, A., Stradella, A., Morilla, I., Falo, C., Vázquez, S., Castany, R., Villanueva, R., Recalde, S., Pérez, V. N., et al. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-019-0367-x · Cited by 15
Multi-omics analysis of the expression and prognostic value of the butyrophilins in breast cancer
Ren, H., Li, S., Liu, X., Li, W., Hao, J., & Zhao, N. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ma0321-158rr · Cited by 18
Metastatic breast cancer: mechanisms and opportunities for cytology
Martins, D. F., de Beça, F. F., & Schmitt, F. C. (2014) · Cytopathology · doi:10.1111/cyt.12158 · Cited by 14
Ács, B., Szekely, N., Szász, A. M., Lotz, G., Székely, T., Istók, R., Székely, E., Madaras, L., Kulka, J., & Járay, B. (2016) · Diagnostic Cytopathology · doi:10.1002/dc.23463 · Cited by 15
Abascal, M. F., Elia, A. M., Alvarez, M., Pataccini, G., Sequeira, G. R., Riggio, M., Figueroa, V., Lamb, C. A., Rojas, P. A., Spengler, E., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33913 · Cited by 15
Yi, J., Tan, S., Zeng, Y., Zou, L., Zeng, J., Zhang, C., Liu, L., & Fan, P. (2022) · Scientific Reports · doi:10.1038/s41598-022-12954-3 · Cited by 14
Brandstetter, L., Jírů-Hillmann, S., Störk, S., Heuschmann, P. U., Wöckel, A., & Reese, J. (2024) · Patient · doi:10.1007/s40271-024-00679-6 · Cited by 16
“In general, the treatment focuses on extending patients’ survival, ensuring adequate symptom management, and promoting quality of life (QoL) [14, 20, 21].”
BackgroundEinarson, T. R., & Machado (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s37003 · Cited by 13
Beck, J. T. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s88037 · Cited by 13
Yu, Y., Wei, C., Qin, Q., Mo, Q., Huang, Z., & Lian, B. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0361-9 · Cited by 14
Factors Associated with Imaging in Patients with Early Breast Cancer After Initial Treatment
Enright, K. A., Desai, T. S., Sutradhar, R., Gonzalez, A. J., Powis, M., Taback, N., Booth, C. M., Trudeau, M., & Krzyzanowska, M. K. (2018) · Current Oncology · doi:10.3747/co.25.3838 · Cited by 12
Gradishar, W. J. (2016) · Cancer Management and Research · doi:10.2147/cmar.s98249 · Cited by 13
Can Women With HER2-Positive Metastatic Breast Cancer Be Cured?
Haji, F., & Hurvitz, S. A. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.06.012 · Cited by 14
Menopausal status does not predict Oncotype DX recurrence score
Carr, D. N., Vera, N., Sun, W., Lee, M. C., Hoover, S. J., Fulp, W. J., Ács, G., & Laronga, C. (2015) · Journal of Surgical Research · doi:10.1016/j.jss.2015.05.034 · Cited by 13
Ohara, M., Akimoto, E., Noma, M., Matsuura, K., Doi, M., KAGAWA, N., & Itamoto, T. (2015) · Oncology Letters · doi:10.3892/ol.2015.3655 · Cited by 13
Mir, M. A., Sofi, S., & Qayoom, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96136-3.00008-x · Cited by 13
Support for Metastatic Breast Cancer Patients—a Systematic Review
Bochenek‐Cibor, J., Górecka, M., Storman, D., & Bała, M. M. (2020) · Journal of Cancer Education · doi:10.1007/s13187-020-01783-5 · Cited by 13
Nano Self-Assembly for Apoptosis Induction and Early Therapeutic Efficacy Monitoring
Meng, X., Cheng, Y., Wang, F., Sun, Z., Chu, H., & Wang, Y. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c02860 · Cited by 12
Pharmacotherapy of bone metastases in breast cancer patients – an update
Jacobs, C. M., Simos, D., Addison, C., Ibrahim, M. F. K., & Clemons, M. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.903925 · Cited by 12
Sysa‐Shah, P., Xu, Y., Guo, X., Pin, S., Bedja, D., Bartock, R., Tsao, A. L., Hsieh, A., Wolin, M. S., Moens, A. L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0965 · Cited by 15
Tsurutani, J., Kuroi, K., Iwasa, T., Miyazaki, M., Nishina, S., Makimura, C., Tanizaki, J., Okamoto, K., Yamashita, T., Aruga, T., et al. (2015) · Cancer Science · doi:10.1111/cas.12658 · Cited by 12
McCutcheon, S., & Cardoso, F. (2015) · The Breast · doi:10.1016/j.breast.2015.06.008 · Cited by 12
Self-citationRau, K.-M., Ou‐Yang, F., Chao, T., Kuo, Y., Cheng, T.-F., Chao, T.-Y., Chen, D., Tzeng, Y. T., Wang, B., Liu, C., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4778-y · Cited by 12
Zheng, A., Guo, B., Zhang, J., & Jin, F. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001415 · Cited by 11
Janni, W., Sarosiek, T., Karaszewska, B., Pikiel, J., Starosławska, E., Potemski, P., Salat, C., Brain, E. G. C., Caglevic, C., Briggs, K. J., et al. (2015) · The Breast · doi:10.1016/j.breast.2015.08.005 · Cited by 11
Ponomarenko, D. M., Gabai, V. L., Sufianov, A. A., Kolesnikov, S. I., & Shneider, A. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27323 · Cited by 11
Romano, P. M., Baraibar, I., Espinós, J., Legaspi, J., López-Picazo, J. M., Aramendía, J. M., Fernández, O. A., & Santisteban, M. (2017) · The Breast Journal · doi:10.1111/tbj.12975 · Cited by 12
Leveraging preclinical models of metastatic breast cancer
Pedroza, D. A., Gao, Y., Zhang, X. H.-F., & Rosen, J. M. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189163 · Cited by 11
Liu, X., Wang, X.-J., Fu, S. W., Wang, M., Kang, H., Guan, H., Zhang, S., Ma, X., Lin, S., Liu, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9024 · Cited by 10
Kourlaba, G., Rapti, V., Alexopoulos, A., Relakis, J., Koumakis, G., Hatzikou, M., Maniadakis, N., & Georgoulias, V. (2015) · BMC Health Services Research · doi:10.1186/s12913-015-0971-4 · Cited by 10
van Es, S. C., Venema, C. M., Glaudemans, A. W. J. M., Hooge, M. N. L., Elias, S. G., Boellaard, R., Hospers, G. A. P., Schroder, C. P., & de Vries, E. G. E. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.157974 · Cited by 10
Isolated Loco-Regional Recurrence of Breast Cancer - Established and Innovative Therapy Concepts
Grischke, E., Wallwiener, D. R., Souchon, R., Fehm, T. N., Loehberg, C. R., Jud, S., Lux, M. P., Beckmann, M. W., & Renner, S. P. (2013) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0032-1328660 · Cited by 10
Hao, Y., Li, N., Fang, A., Koo, V., Peeples, M., Kageleiry, A., Wu, E. Q., & Guérin, A. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0328-3 · Cited by 10
Jin, L., Chen, K., Tan, C., Li, J., Luo, J., Yang, Y., Li, Y., Li, S., Zhu, L., Hu, Y., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-1006 · Cited by 10
The emerging potentials of lncRNA DRAIC in human cancers
Yao, Q., Zhang, X., & Chen, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.867670 · Cited by 10
Kim, J., Shin, J., Ahn, J. S., Park, Y. H., & Im, Y. (2023) · Cancers · doi:10.3390/cancers15133431 · Cited by 10
“Before the era of CDK4/6 inhibitors, non-steroidal AI was considered the first-line treatment for HR+HER2− MBC without visceral crisis [19].”
BackgroundJérusalem, G., Neven, P., Marinsek, N., Zhang, J., Degun, R., Benelli, G., Saletan, S., Ricci, J.-F., & André, F. (2015) · BMC Cancer · doi:10.1186/s12885-015-1762-3 · Cited by 10
Pei, R., Xu, Y., Yan, W., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0247-5 · Cited by 10
“Metastatic breast cancer is a biologically heterogeneous disease, and some metastatic breast cancer patients may have relatively longer survival than others [2].”
BackgroundYip, C. H. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24560 · Cited by 10
Long‑responders to anti‑HER2 therapies: A�case�report and review of the literature
Cantini, L., Pistelli, M., Savini, A., Bastianelli, L., Mora, A. D., Merloni, F., Burattini, M., & Berardi, R. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1495 · Cited by 11
Huang, L., Wang, X., Zhou, L., Di, L., Zheng, H., Jiang, Z., Wang, Y., Song, X., Feng, J., Yu, S., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-04000-3 · Cited by 11
Schmitt, F. C., & Vielh, P. R. (2014) · Histopathology · doi:10.1111/his.12439 · Cited by 10
Goyal, R., Holmes, H. M., Chen, H., Abughosh, S., Candrilli, S. D., & Johnson, M. L. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06845-4 · Cited by 9
Wittayanukorn, S., Qian, J., Westrick, S. C., Billor, N., Johnson, B., & Hansen, R. A. (2014) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2014.12.002 · Cited by 11
Wang, P. (2015) · Medical Science Monitor · doi:10.12659/msm.893585 · Cited by 9
Estimating treatment effects in observational studies with both prevalent and incident cohorts
Ning, J., Hong, C., Li, L., Huang, X., & Shen, Y. (2017) · Canadian Journal of Statistics · doi:10.1002/cjs.11317 · Cited by 9
Kawaguchi, H., Masuda, N., Nakayama, T., Aogi, K., Anan, K., Ito, Y., Ohtani, S., Sato, N., Saji, S., Takano, T., et al. (2019) · Breast Cancer · doi:10.1007/s12282-019-01029-3 · Cited by 9
Can we cure oligometastatic disease? A practical point of view
Pérez-García, J. M., Cortez, P., Gión, M., & Cortés, J. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000684 · Cited by 9
Arpino, G., Marmé, F., Cortés, J., Ricevuto, E., Leonard, R. C., & Llombart‐Cussac, A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.007 · Cited by 9
Puglisi, F., Rea, D. W., Kroes, M., & Pronzato, P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.012 · Cited by 9
Li, N., Hao, Y., Kageleiry, A., Peeples, M., Fang, A., Koo, V., Wu, E. Q., & Guérin, A. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1130691 · Cited by 9
Mansour, M., & Mourad, C. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2216-8 · Cited by 9
Tailor, N. K., Grewal, A. S., Deswal, G., & Dhingra, A. K. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206312324240805075050 · Cited by 8
Abo-Touk, N. A. (2016) · Cancer Research Journal · doi:10.11648/j.crj.20160402.12 · Cited by 8
Rodriguez-Rincon, D., Leach, B., d’Angelo, C., Harshfield, A., & Manville, C. M. (2019) · RAND Corporation eBooks · doi:10.7249/rr3010.4 · Cited by 9
Wallwiener, M., Nabieva, N., Feißt, M., Fehm, T. N., Waal, J. D., Rezai, M., Baier, B., Baake, G., Kolberg, H., Guggenberger, M., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5806-y · Cited by 10
Self-citationNukatsuka, M., Saitô, H., Noguchi, S., & Takechi, T. (2019) · In Vivo · doi:10.21873/invivo.11622 · Cited by 9
On behalf of GEICAM, S. B. C. G., Barnadas, A., Muñoz-Mateu, M., Vila, M. M., Chacón, J. I., Cassinello, J., Antolín, S., Adrover, E., Ramos, M., Carrasco, E., et al. (2019) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-019-0161-y · Cited by 8
Lapčík, P., Pospisilova, A., Janáčová, L., Grell, P., Fabián, P., & Bouchal, P. (2020) · Cancers · doi:10.3390/cancers12092638 · Cited by 8
Díaz, S., Briceño-Morales, X., Puerto-Horta, L. J., Lehmann-Mosquera, C., Orozco-Ospino, M., Guzmán-Abisaab, L., Ángel-Aristizábal, J., García, M., Duarte, C., Lozano, I. F. M., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab023 · Cited by 8
Nakata, E., Sugihara, S., Osumi, S., & Yamashita, N. (2017) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2017.03.014 · Cited by 9
“In the 2007 guideline of the American Society of Clinical Oncology (ASCO) and in the 2012 Clinical Practice Guidelines of the European Society for Medical Oncology (ESMO), use of CEA is recommended for monitoring response to treatment in breast cancer patients with metastatic disease in conjunction with diagnostic ima…”
Rollando, R. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i7.25607 · Cited by 10
Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer
Goodin, S., Barbour, S. Y., Song, J., Berrak, E., & Cox, D. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140773 · Cited by 7
Design and computational analysis of a novel Azurin-BR2 chimeric protein against breast cancer
Rehman, H. M., Yousaf, N., Hina, S. M., Nadeem, T., Ansari, M. A., Chaudry, A., Kafait, I., Khalid, S., Alanzi, A. R., & Bashir, H. (2024) · Toxicology Research · doi:10.1093/toxres/tfae179 · Cited by 7
Disease-related surgery in patients with distant metastatic breast cancer
Amann, E., Huang, D. J., Weber, W. P., Eppenberger‐Castori, S., Schmid, S. M., Hess, T. H., & Güth, U. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.08.015 · Cited by 7
Errico, V., Perroni, G., Milana, F., Lisa, A. V. E., Marrazzo, E., Klinger, M. E. A., Tinterri, C., & Testori, A. (2021) · Gland Surgery · doi:10.21037/gs-20-860 · Cited by 7
A Real-World Study on Oral Vinorelbine for the Treatment of Metastatic Breast Cancer
Huang, J., Bai, X. L., Xie, X., Chen, L., Lan, X., Zhang, Q., Song, L., Hong, P., & Du, C. (2022) · ONCOLOGIE · doi:10.32604/oncologie.2022.019881 · Cited by 7
Karanyotova, S., Topova, B., Petrova, E., Doychev, P., Kapitanska, E., Petrova, G. I., Mitkova, Z. E., & Dimitrova, M. J. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1073733 · Cited by 7
Zhang, Q., Lan, X., Huang, J., Xie, X., Chen, L., Song, L., Bai, X., Chen, X., Jing, H., & Du, C. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231206986 · Cited by 7
Drooger, J. C., van Pelt-Sprangers, J. M., Leunis, C., Jager, A., & de Jongh, F. E. (2015) · Medical Oncology · doi:10.1007/s12032-015-0550-x · Cited by 7
Wang, Y., Liu, J., Jia, W., Li, S., Rao, N., Su, F., Liu, Q., & Yao, H. (2016) · Chemotherapy · doi:10.1159/000448472 · Cited by 8
Metadata
- Authors
- Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E.
- Affiliations
- European School of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- Brighton and Sussex Medical School (GB)
- Europa Donna (IT)
- Gdańsk Medical University (PL)
- Corresponding author
- Senkus, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 23
- Pages
- vii11-vii19
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4234749243
- Cited by
- 485
- References
- 40
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 21 · 2023: 25 · 2022: 26 · 2021: 30 · 2020: 37 · 2019: 41 · 2018: 33 · 2017: 53 · 2016: 42 · 2015: 66 · 2014: 49 · 2013: 32 · 2012: 1
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2625 d)
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- locally recurrent breast cancer, metastatic breast cancer, breast cancer diagnosis, breast cancer treatment, breast cancer follow-up, incidence, mortality, early detection, adjuvant systemic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.